1. Anticoagulation and AF: Emerging Insights
Professor the Lord Kakkar
Thrombosis Research Institute and
University College London

2. Register of Interests for Ajay Kakkar
Research Support/P.I.
Bayer HealthCare, Sanofi-Aventis, Boehringer Ingelheim, Pfizer, Bristol–Myers Squibb, Eisai
Employee
N/A
Consultant
Bayer HealthCare, Sanofi-Aventis, Boehringer Ingelheim, Pfizer, Bristol–Myers Squibb, Eisai, Novartis, Adventrix, Daiichi Sankyo, Shire
Major Stockholder
Speakers Bureau
Honoraria
Bayer HealthCare, Sanofi-Aventis, Boehringer Ingelheim, Pfizer, Bristol–Myers Squibb, Eisai, GSK
Scientific Advisory Board
Bayer HealthCare, Sanofi-Aventis, Boehringer Ingelheim, Pfizer, Bristol–Myers Squibb, Eisai, Novartis, Daiichi Sankyo

3. The Global Anticoagulant Registry in the Field: Ongoing representative, worldwide outcomes research programme
Independent academic research initiative
55,000 newly-diagnosed AF patients in 34 countries
Randomized selection of sites representative of national AF care settings
Unselected prospective patients enrolled consecutively
Long-term follow-up (minimum of 2 years, up to 8 years)
5 sequential prospective cohorts
Extensive monitoring (20% of CRFs)
2010
2011
2012
2013
2014
2015
2016
2017
2018
Cohort 1
Dec-09
Oct-13
Jun-18
Cohort 2
Oct-11
Jun-15
Recruitment
Cohort 3
Jun-13
Jun-16
Minimum follow-up
Cohort 4
Aug-14
Jun-17
Extended follow-up
Cohort 5
Jul-15

4. The Global Anticoagulant Registry in the Field: Already one of the largest outcomes research programmes in AF
34,205 AF patients recruited in 34 countries
29,117 prospective patients
Cohort 3 recruitment completed July 2014 (n=11,405)
Cohort 4 recruitment opened August 2014 (n=456)
2010
2011
2012
2013
2014
2015
2016
2017
2018
Cohort 1
Dec-09
Oct-13
Jun-18
Cohort 2
Oct-11
Jun-15
Recruitment
Cohort 3
Jun-13
Jun-16
Minimum follow-up
Cohort 4
Aug-14
Jun-17
Extended follow-up
Cohort 5
Jul-15

5. Antithrombotic prescribing patterns in Garfield-AF
Dec 09-Oct 11
Oct 11-Jun 13
Jun 13-Jun 14
Dec 09-Jun14
Preliminary data
30 June 2014
N=10,278
N=11,557
N=9831
N=31,666

6. The use of NOACs has increased
Dec 09-Oct 11
Oct 11-Jun 13
Jun 13-Jun 14
Dec 09-Jun13
Preliminary data
30 June 2014

7. Acknowledgements
This research programme would not be possible without the hard work and dedication of the:
Steering Committee
National Coordinator Council
Garfield-AF Investigators

8. Anticoagulation and AF: Emerging Insights Agenda
Understanding risk, Professor Dan Atar
The role of anticoagulants, Professor Keith Fox
Preventing a second stroke, Professor John Camm
Lessons beyond AF, Professor Samuel Z Goldhaber
Future challenges, Professor Alexander GG Turpie
Panel discussion: Stroke prevention in AF 2014,
Case Presenter: Professor Sylvia Haas Discussant: Dr Bernard J Gersh
Closing remarks, Professor Jean-Pierre Bassand